TRCT
LBRX

Tower Research Capital (TRC)’s LB Pharmaceuticals LBRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7K Sell
762
-899
-54% -$26.4K ﹤0.01% 3356
2026
Q1 		$41K Buy
1,661
+300
+22% +$6.92K ﹤0.01% 2924
2025
Q4 		$30.3K Buy
+1,361
New +$23.8K ﹤0.01% 2804

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Tower Research Capital (TRC)'s LBRX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its LB Pharmaceuticals (LBRX) stake by 54% in Q2 2026, selling an estimated $26.4K and leaving 762 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3356.

Tower Research Capital (TRC) first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $41K in Q1 2026. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Tower Research Capital (TRC) held 762 shares of LB Pharmaceuticals worth $24.7K as of Q2 2026.
  • Tower Research Capital (TRC) sold 899 LB Pharmaceuticals shares in Q2 2026, an estimated $26.4K.
  • LB Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3356 holding.
  • Tower Research Capital (TRC) first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Tower Research Capital (TRC)'s LB Pharmaceuticals position peaked at $41K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.